NEW YORK (GenomeWeb) – Scipio Bioscience said today that it has completed a seed financing round of €1.2 million ($1.4 million) to fund development and commercialization of its first prototype kit for single-cell transcriptomics.

Paris-based Seventure Partners' Quadrivium I seed fund and Bonn, Germany-based High-Tech Gründerfonds participated in the funding.

Scipio uses a proprietary technology based on barcoding in a test tube format to prepare samples for single-cell profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.